News &amp; Updates

The tricyclic antidepressant nortriptyline is only as good as placebo in terms of reducing symptoms of functional dyspepsia in preselected patients, according to the results of a multicentre randomized controlled trial.

Nortriptyline misses mark in functional dyspepsia trial

PFS gains seen with savolitinib–osimertinib combo in EGFR-mutant, MET-amplified NSCLC

Treatment with the combination of savolitinib plus osimertinib prolongs progression-free survival (PFS) in patients with non-small cell lung cancer (NSCLC) harbouring EGFR mutation and MET amplification, as shown in the phase III SACHI trial.

PFS gains seen with savolitinib–osimertinib combo in EGFR-mutant, MET-amplified NSCLC

GLP-1RA bests aspirin for CRC prevention

Use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) appears to confer greater protection against the development of colorectal cancer (CRC) as compared with aspirin, according to a retrospective study.

GLP-1RA bests aspirin for CRC prevention

Zanidatamab outdoes trastuzumab as first-line treatment of HER2-positive mGEA

Treatment with zanidatamab combined with tislelizumab and/or chemotherapy (CT) significantly improves progression-free survival (PFS) in patients with HER2-positive locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma (mGEA), as shown in the primary analysis from HERIZON-GEA-01.

Zanidatamab outdoes trastuzumab as first-line treatment of HER2-positive mGEA

$Add-on tafasitamab prolongs PFS in relapsed, refractory follicular lymphoma$

Add-on tafasitamab prolongs PFS in relapsed, refractory follicular lymphoma

In the treatment of patients with relapsed or refractory follicular lymphoma, adding tafasitamab to lenalidomide and rituximab appears to improve progression-free survival (PFS) while having an acceptable safety profile, according to the phase III inMIND study.

Add-on tafasitamab prolongs PFS in relapsed, refractory follicular lymphoma

CGM in diabetes: From evidence to practice

Continuous glucose monitoring (CGM) is transforming diabetes care in both type 1 diabetes (T1D) and type 2 diabetes (T2D), with or without insulin use, said Dr Pratik Choudhary, Honorary Consultant and Professor at the University of Leicester, UK, during an Abbott-sponsored symposium at ATTD-Asia 2025 in Singapore.

CGM in diabetes: From evidence to practice

06 Feb 2026

Adjuvant S-1 + oxaliplatin yields survival benefit in G/GEJ cancer

Combining S-1 and oxaliplatin (SOX) as an adjuvant chemotherapy significantly improves overall survival (OS) and disease-free survival (DFS) compared with S-1 alone in patients with gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, according to the final results of the CAPITAL trial presented at ASCO GI 2026.

Adjuvant S-1 + oxaliplatin yields survival benefit in G/GEJ cancer